Silver Oak Securities’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$545K Buy
8,983
+2,137
+31% +$125K 0.04% 407
2025
Q4
$371K Sell
6,846
-3,726
-35% -$179K 0.03% 554
2025
Q3
$477K Buy
10,572
+4,278
+68% +$200K 0.04% 441
2025
Q2
$291K Sell
6,294
-120
-2% -$5.89K 0.02% 547
2025
Q1
$385K Sell
6,414
-583
-8% -$34K 0.04% 432
2024
Q4
$392K Buy
6,997
+3,030
+76% +$169K 0.04% 438
2024
Q3
$200K Buy
+3,967
New +$186K 0.02% 490

Other funds holding BMY

Silver Oak Securities's BMY Position: Q1 2026 in Review

Silver Oak Securities increased its Bristol-Myers Squibb (BMY) stake by 31% in Q1 2026, buying an estimated $125K and bringing the position to 8,983 shares worth $545K. The position accounts for 0.04% of the portfolio, ranked #407.

Silver Oak Securities first reported a position in BMY in Q3 2024 and has held it in 7 quarters since. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Silver Oak Securities held 8,983 shares of Bristol-Myers Squibb worth $545K as of Q1 2026.
  • Silver Oak Securities bought 2,137 Bristol-Myers Squibb shares in Q1 2026, an estimated $125K.
  • Bristol-Myers Squibb made up 0.04% of Silver Oak Securities's portfolio in Q1 2026, its #407 holding.
  • Silver Oak Securities first reported a position in Bristol-Myers Squibb in Q3 2024 and has held it in 7 quarters since.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Silver Oak Securities's 13F filing for Q1 2026, filed 20 Apr 2026.